Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

CanSino Biologics Inc

Healthcare US CASBF

2.86USD
0.00(0%)

Last update at 2026-06-18T20:00:00Z

Day Range

3.974.10
LowHigh

52 Week Range

3.206.99
LowHigh

Fundamentals

  • Previous Close 2.86
  • Market Cap1853.34M
  • Volume1200
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA76.55M
  • Revenue TTM1067.91M
  • Revenue Per Share TTM4.21
  • Gross Profit TTM 804.23M
  • Diluted EPS TTM-0.1

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax 21.18M -381.20400M -1978.88400M -1184.00100M 1936.79M
Minority interest - 4.79M 510.95M 55.33M 7.30M
Net income 27.15M -378.88400M -1482.73200M -909.43100M 1914.39M
Selling general administrative - 194.36M 294.45M 278.07M 231.81M
Selling and marketing expenses - 369.05M 353.40M 266.61M 105.82M
Gross profit 681.87M 580.45M -876.01900M -186.60700M 3003.22M
Reconciled depreciation - 211.38M 269.05M 196.36M 88.54M
Ebit -113.12927M -321.22200M -1914.74000M -1225.52800M 1888.45M
Ebitda 60.98M -109.83900M -1645.68600M -1029.16800M 1976.99M
Depreciation and amortization 174.11M 211.38M 269.05M 196.36M 88.54M
Non operating income net other - - - - -
Operating income -113.12927M -403.39000M -2035.18200M -1368.74200M 1911.61M
Other operating expenses 1145.18M 1228.27M 2380.36M 2479.61M 2497.84M
Interest expense 55.81M 59.98M 64.14M 41.34M 20.42M
Tax provision - 2.47M -62.23670M -219.24400M 29.70M
Interest income - 63.87M 96.51M 65.93M 79.65M
Net interest income - 3.71M 36.26M 24.10M 58.96M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -5.97668M 2.47M -11.45115M -219.24400M 29.70M
Total revenue 1032.05M 824.88M 345.18M 1031.04M 4299.70M
Total operating expenses 795.00M 983.84M 1159.16M 1261.96M 1201.35M
Cost of revenue 350.18M 244.43M 1221.20M 1217.65M 1296.49M
Total other income expense net 134.31M 22.19M 56.30M 184.74M 25.18M
Discontinued operations - - - - -
Net income from continuing ops - -383.67100M -1930.99471M -964.75700M 1907.09M
Net income applicable to common shares - - - -909.43100M 1914.39M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 7185.23M 7958.13M 9369.61M 11468.96M 11874.19M
Intangible assets 224.62M 271.60M 205.65M 258.74M 198.31M
Earning assets - - - - -
Other current assets 63.67M 13.18M 16.37M 245.04M 454.49M
Total liab 2052.10M 3048.26M 3865.47M 4223.36M 3326.30M
Total stockholder equity 4956.12M 4909.87M 5274.60M 6748.09M 7995.05M
Deferred long term liab - - - 51.95M 26.19M
Other current liab 652.72M 788.00M 992.24M 1064.61M 920.41M
Common stock 247.17M 247.45M 247.45M 247.45M 247.45M
Capital stock - 247.45M 247.45M 247.45M 247.45M
Retained earnings -471.68113M -1937.29800M -1558.41386M -75.68200M 1031.31M
Other liab - - - 222.35M 202.04M
Good will - - - - -
Other assets - - - 398.73M -126.58800M
Cash 1236.39M 1556.46M 2058.20M 3394.82M 5456.87M
Cash and equivalents - - - - -
Total current liabilities 1083.02M 1772.04M 2565.30M 2942.07M 2874.94M
Current deferred revenue 55.72M - 3.57M 810.72M -
Net debt 52.78M 456.91M 656.66M -694.19400M -4082.05500M
Short term debt 324.11M 902.16M 1465.52M 1624.34M 1111.97M
Short long term debt - 892.17M 1394.87M 1575.58M 1080.79M
Short long term debt total 1289.16M 2013.37M 2714.86M 2700.63M 1374.82M
Other stockholder equity 5141.33M 6599.72M 6568.47M 6576.32M 6716.29M
Property plant equipment - - - 3069.00M 2218.30M
Total current assets 3840.77M 4282.49M 5180.83M 7730.19M 9289.84M
Long term investments - - - - -
Net tangible assets - - - 6527.17M 7822.93M
Short term investments 1409.15M 1639.02M 2071.67M 2551.97M 2326.03M
Net receivables 793.09M 793.30M 647.13M 855.49M 177.08M
Long term debt - 1098.54M 1065.66M 878.01M 40.00M
Inventory 338.48M 280.52M 387.45M 677.78M 875.62M
Accounts payable 50.46M 62.47M 103.97M 253.12M 842.57M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 39.30M 0.22M 17.10M - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 27.29M 1697.01M 84.57M 5404.67M 2448.46M
Deferred long term asset charges - - - - -
Non current assets total 3344.46M 3675.64M 4188.78M 3738.78M 2584.34M
Capital lease obligations - 22.67M 239.82M 247.04M 254.03M
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - 3.96M 519.86M -1191.95500M -1403.04800M
Change to liabilities - - - -859.90700M 1239.96M
Total cashflows from investing activities 355.39M 3.96M -449.64586M -1227.64100M -2560.41200M
Net borrowings - -260.00100M 69.28M 1246.05M 969.13M
Total cash from financing activities -703.08371M -334.18400M -7.58209M 854.60M 1559.92M
Change to operating activities - - - - -
Net income 27.15M -381.20400M -1978.88400M -1184.00100M 1907.09M
Change in cash -263.78385M -490.29400M -1345.16900M -2064.18800M 1009.43M
Begin period cash flow 1500.17M 2046.10M 3391.27M 5455.46M 4446.03M
End period cash flow 1236.39M 1555.81M 2046.10M 3391.27M 5455.46M
Total cash from operating activities 32.49M -168.78700M -908.22751M -1887.59900M 2014.56M
Issuance of capital stock - 7.03M 16.98M - 0.00000M
Depreciation 174.11M 211.38M 269.05M 196.36M 88.54M
Other cashflows from investing activities 12.12M -104.85200M -47.79326M 107.16M 45.77M
Dividends paid - 63.78M 3.63M -193.93200M 14.10M
Change to inventory -79.20880M 0.02M -216.54244M -604.01900M -706.39200M
Change to account receivables -53.78915M -77.67000M 265.97M -495.79600M -419.93500M
Sale purchase of stock - -6.96200M 17.09M -150.16900M -
Other cashflows from financing activities -7.15058M -10.47200M -90.21809M 2564.40M 1719.92M
Change to netincome - - - 821.25M -66.56800M
Capital expenditures 185.33M 457.64M 610.47M 1075.01M 1203.14M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -159.97437M -115.79000M -156.95500M -1478.95600M 84.31M
Stock based compensation - 3.20M 9.54M 10.08M 9.80M
Other non cash items -8.80185M 113.62M 960.47M 568.91M -75.18100M
Free cash flow -152.84229M -626.42500M -1526.72200M -2962.61200M 811.42M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
CASBF
CanSino Biologics Inc		 - -% 2.86 - - 1.74 1.32 11.66 1.87
ZTS
Zoetis Inc		 -2.135 2.71% 76.58 40.18 30.96 10.67 17.60 11.27 26.18
MKKGY
Merck KGaA ADR		 -0.19 0.62% 30.56 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien		 - -% 157.12 21.73 14.95 3.16 2.15 3.56 12.82
GALDY
GALDERMA GROUP AG		 -0.12 0.28% 42.82 74.21 41.67 8.64 5.55 9.15 42.22

Reports Covered

Stock Research & News

View All

Profile

CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People's Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It develops DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary vaccination. In addition, it develops Tdcp Adolescent and Adult vaccine for treating pertussis; PBPV, a serotype-independent protein-based pneumococcal vaccine that is in Phase I clinical trial; PCV13i, a pneumococcal conjugate vaccine, which is in Phase I clinical trial; and TB Booster for the BCG-vaccinated population which is in Phase I clinical trial. Further, it is developing various preclinical stage products, including DTcP-Hib Combo vaccine; CS-2023 to treat meningitis; CS-2028 for treating multivalent conjugate vaccine; CS-2032 for hingles; CS-2036 to treat polio; CS-2047 for treating tetanus; and CS-2201 DTcP for combination vaccine. The company was incorporated in 2009 and is headquartered in Tianjin, the People's Republic of China.

CanSino Biologics Inc

401-420, Biomedical Park, Tianjin, China, 300457

Key Executives

Name Title Year Born
Dr. Xuefeng Yu Ph.D. Co-Founder, Chairman, CEO & GM 1964
Dr. Tao Zhu Ph.D. Co-Founder, Exec. Director, Deputy GM & Chief Scientific Officer 1974
Dr. Dongxu Qiu MBA, Ph.D. Co-Founder, Exec. VP, Exec. Director & Deputy GM 1961
Ms. Xi Luo Chief Financial Officer 1977
Dr. Shou-Bai Chao Exec. Director, COO & Deputy GM 1963
Mr. Chunlin Xin Sr. Director of New Technology Department NA
Mr. Yonghui Wu VP of Marketing NA
Ms. Jing Wang Chief Commercial Officer, Deputy GM & Exec. Director 1981
Mr. Ming King Chiu FCIS, FCS Joint Company Sec. 1977
Dr. Xuefeng Yu Ph.D. Co-Founder, Executive Chairman, CEO & GM 1965

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.